Skip Navigation

Cardiovascular Research 1998 40(1):206-210; doi:10.1016/S0008-6363(98)00103-5
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Saijonmaa, O.
Right arrow Articles by Fyhrquist, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saijonmaa, O.
Right arrow Articles by Fyhrquist, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells

Outi Saijonmaa* and Frej Fyhrquist

Minerva Institute for Medical Research and Department of Internal Medicine, Helsinki University Central Hospital, Helsinki, Finland

* Corresponding author. Address for correspondence: Minerva Institute for Medical Research, Tukholmankatu 2, SF-00250 Helsinki, Finland. Tel.: +358 (0) 477 1004; Fax: +358 (0) 477 1025; E-mail: outi.saijonmaa@kruuna.helsinki.fi

Objective: To examine the role of atrial natriuretic peptide (ANP) and cyclic GMP in the regulation of angiotensin converting enzyme (ACE) in cultured human endothelial cells. Methods: Cultured endothelial cells from human umbilical veins (HUVEC) were treated with ANP (0.3–30 nM), 8-Br-cGMP (1–100 µM), Rp-8-Br-PET-cGMPS (1 µM), or the phosphodiesterase inhibitors, zaprinast (10–100 µM), dipyridamole (1–10 µM), or isobutyl methyl xanthine (IBMX, 0.1–0.5 mM). ACE amounts were measured by inhibitor binding assay and cellular cGMP levels by radioimmunoassay. Results: ANP caused a dose dependent increase in ACE measured in intact endothelial cell culture. The stimulatory effect of ANP was blocked by Rp-8-Br-PET-cGMPS, a protein kinase G inhibitor. The cyclic GMP analog, 8-Br-cGMP and the cyclic GMP specific phosphodiesterase inhibitor, zaprinast, both increased ACE. Increase of ACE was also caused by nonspecific phosphodiesterase inhibitors, dipyridamole and IBMX. Intracellular cGMP levels were shown to increase by ANP, and phosphodiesterase inhibitors. Conclusions: These data suggest that cGMP is an intracellular mediator regulating ACE and that ANP induced increase of ACE is mediated via a cGMP dependent mechanism.

KEYWORDS Angiotensin converting enzyme; Atrial natriuretic peptide; Cyclic GMP; Phosphodiesterase inhibitors; HUVEC


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.